China SXT Pharmaceuticals, Inc. cash flow statement

In fiscal 2026, China SXT Pharmaceuticals, Inc.'s operations generated −$4.0m of cash; it spent $0 on capital projects, leaving free cash flow of −$4.0m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

China SXT Pharmaceuticals, Inc.: cash flow statement, annual
Fiscal year	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Cash from operations	293	1,920	239	934	−1,317	268	−81	−1,928	−2,345	−4,017
Depreciation and amortisation	94	129	181	332	345	320	250	203	82	74
Stock-based pay	—	—	—	—	—	2,334	555	352	—	5,306
Capital spending	179	436	536	131	78	61	—	7	2	0
Free cash flow	114	1,484	−297	803	−1,395	207	—	−1,935	−2,347	−4,017
Free cash flow after stock pay	—	—	—	—	—	−2,127	—	−2,287	—	−9,323
Shares issued	—	—	—	—	—	−30	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SXTC vs SXTP LPCN vs SXTC SCNX vs SXTC NTRB vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China SXT Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to China SXT Pharmaceuticals, Inc.